AlphaQuest LLC Makes New $39,000 Investment in Evolus, Inc. $EOLS

AlphaQuest LLC purchased a new position in Evolus, Inc. (NASDAQ:EOLS) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 3,247 shares of the company’s stock, valued at approximately $39,000.

Several other institutional investors have also added to or reduced their stakes in EOLS. IFP Advisors Inc raised its position in Evolus by 99.0% in the first quarter. IFP Advisors Inc now owns 9,427 shares of the company’s stock worth $113,000 after acquiring an additional 4,691 shares during the period. Rafferty Asset Management LLC purchased a new stake in Evolus in the fourth quarter worth about $115,000. Man Group plc purchased a new stake in Evolus in the fourth quarter worth about $121,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Evolus in the first quarter worth about $151,000. Finally, ProShare Advisors LLC increased its position in Evolus by 31.0% in the fourth quarter. ProShare Advisors LLC now owns 18,563 shares of the company’s stock worth $205,000 after buying an additional 4,392 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

EOLS has been the subject of a number of analyst reports. Needham & Company LLC restated a “hold” rating and issued a $22.00 price target on shares of Evolus in a research report on Wednesday, August 6th. Wall Street Zen cut Evolus from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. HC Wainwright decreased their price objective on shares of Evolus from $27.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Finally, BTIG Research decreased their price objective on shares of Evolus from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Evolus has an average rating of “Moderate Buy” and an average target price of $21.25.

Insider Activity at Evolus

In related news, insider David Moatazedi sold 111,323 shares of the firm’s stock in a transaction on Friday, June 13th. The shares were sold at an average price of $10.05, for a total transaction of $1,118,796.15. Following the completion of the transaction, the insider directly owned 381,509 shares of the company’s stock, valued at approximately $3,834,165.45. This trade represents a 22.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Albert G. White III bought 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The shares were bought at an average cost of $9.45 per share, with a total value of $189,000.00. Following the completion of the purchase, the director directly owned 50,378 shares of the company’s stock, valued at $476,072.10. This represents a 65.84% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 133,627 shares of company stock valued at $1,325,764. Insiders own 5.90% of the company’s stock.

Evolus Stock Up 1.8%

Shares of EOLS stock opened at $7.51 on Friday. The company has a market capitalization of $485.75 million, a price-to-earnings ratio of -7.66 and a beta of 1.07. Evolus, Inc. has a one year low of $5.71 and a one year high of $17.82. The company’s fifty day moving average price is $8.29 and its 200-day moving average price is $10.24. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.